相似文献
1
Special Issue "Pathophysiology and Treatment of Alzheimer's Disease".
Int J Mol Sci. 2024 May 30;25(11):6015. doi: 10.3390/ijms25116015.
2
Souvenaid for Alzheimer's disease.
Cochrane Database Syst Rev. 2020 Dec 15;12(12):CD011679. doi: 10.1002/14651858.CD011679.pub2.
3
A paradigm shift for evaluating pharmacotherapy for Alzheimer's disease: the 10-patient screening protocol.
Consult Pharm. 2013 Jul;28(7):443-54. doi: 10.4140/TCP.n.2013.443.
4
Nimodipine for primary degenerative, mixed and vascular dementia.
Cochrane Database Syst Rev. 2002(3):CD000147. doi: 10.1002/14651858.CD000147.
5
Special Issue "Commemorative Issue Celebrating the 20th Anniversary of the Alzheimer's Foundation of America: Understanding and Treating Alzheimer's Disease".
Medicina (Kaunas). 2024 Apr 26;60(5):712. doi: 10.3390/medicina60050712.
6
Latest treatment options for Alzheimer's disease, Parkinson's disease dementia and dementia with Lewy bodies.
Expert Opin Pharmacother. 2014 Sep;15(13):1797-810. doi: 10.1517/14656566.2014.936848. Epub 2014 Jul 3.
7
Nimodipine for primary degenerative, mixed and vascular dementia.
Cochrane Database Syst Rev. 2001(1):CD000147. doi: 10.1002/14651858.CD000147.
8
Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
Pharmacol Res. 2005 Jan;51(1):1-17. doi: 10.1016/j.phrs.2004.05.005.
9
New and emerging treatments for Alzheimer's disease.
Expert Rev Neurother. 2012 May;12(5):535-43. doi: 10.1586/ern.12.43.
10
A Recent Update on Pathophysiology and Therapeutic Interventions of Alzheimer's Disease.
Curr Pharm Des. 2023;29(43):3428-3441. doi: 10.2174/0113816128264355231121064704.
本文引用的文献
1
Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer's and Parkinson's diseases.
Tissue Barriers. 2024 Oct;12(4):2292461. doi: 10.1080/21688370.2023.2292461. Epub 2023 Dec 14.
2
The Effects of NLY01, a Novel Glucagon-Like Peptide-1 Receptor Agonist, on Cuprizone-Induced Demyelination and Remyelination: Challenges and Future Perspectives.
Neurotherapeutics. 2023 Jul;20(4):1229-1240. doi: 10.1007/s13311-023-01390-4. Epub 2023 Jun 9.
3
Cure of Alzheimer's Dementia Requires Addressing All of the Affected Brain Cell Types.
J Clin Med. 2023 Mar 4;12(5):2049. doi: 10.3390/jcm12052049.
4
Insulin signaling as a therapeutic mechanism of lithium in bipolar disorder.
Transl Psychiatry. 2022 Aug 29;12(1):350. doi: 10.1038/s41398-022-02122-6.
5
GLP-1 receptor nitration contributes to loss of brain pericyte function in a mouse model of diabetes.
Diabetologia. 2022 Sep;65(9):1541-1554. doi: 10.1007/s00125-022-05730-5. Epub 2022 Jun 10.
6
Lithium treatment and human hippocampal neurogenesis.
Transl Psychiatry. 2021 Oct 30;11(1):555. doi: 10.1038/s41398-021-01695-y.
7
The role of glia in the physiology and pharmacology of glucagon-like peptide-1: implications for obesity, diabetes, neurodegeneration and glaucoma.
Br J Pharmacol. 2022 Feb;179(4):715-726. doi: 10.1111/bph.15683. Epub 2021 Nov 23.
8
Mini review: Recent advances on epigenetic effects of lithium.
Neurosci Lett. 2021 Sep 14;761:136116. doi: 10.1016/j.neulet.2021.136116. Epub 2021 Jul 16.
9
Effect of lithium on circadian rhythm in bipolar disorder: A systematic review and meta-analysis.
Bipolar Disord. 2021 Aug;23(5):445-453. doi: 10.1111/bdi.13070. Epub 2021 Mar 16.
10
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial.
Lancet Neurol. 2020 Jul;19(7):582-590. doi: 10.1016/S1474-4422(20)30173-3.
Zotero 插件